Skip to content
Home/Companies/MedTech/PathXL

PathXL

MedTech·UK·Exited 2016·Held 4yr
Entry
2012
Hold
4yr
Exit
2016

Who owns PathXL?

PathXL was owned by Clarendon Fund Managers through Co-Fund NI (2012 vintage) from 2012 to 2016, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-08

Clarendon Fund Managers
Investor
Clarendon Fund Managers
Co-Fund NI · 2012 · VC

Key facts

HQUnited Kingdom
SectorMedTech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2016

More from Co-Fund NI

Other portfolio companies in the same fund.

GenoME Diagnostics
GenoME Diagnostics
Active
BiotechUK· 2023
Kinsetsu
Active
SaaSUK· 2023
Amply
Amply
Active
BiotechUK· 2022
Angoka
Angoka
Active
CybersecurityUK· 2022
Aramune Technologies
Aramune Technologies
Active
BiotechUK· 2022
CV6 Therapeutics
CV6 Therapeutics
Active
BiotechUK· 2022

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany
Track PathXL

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy PathXL?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on PathXL.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue